Microphage Inc. Announces the Formation of Its Medical Advisory Board

LONGMONT, CO--(Marketwire - May 12, 2011) -

MicroPhage, Inc. announced today that it has formed a Medical Advisory Board to guide the Company as it moves into the commercialization phase of its novel diagnostic technology. The board is comprised of four internationally recognized clinicians in the field of pathogenic bacteria and antibiotic susceptibility. Richard Proctor, M.D., will chair the committee.

“The creation of a strong, influential Medical Advisory Board highlights our commitment to the advancement of our clinical diagnostic platform,” said Donald Mooney, President and Chief Executive Officer of MicroPhage. “We are encouraged by our clinical trial performance and recognize the immense potential of our technology. The Medical Advisory Board will play a critical role in guiding our application of this technology to maximize benefit to the healthcare community.”

The members Medical Advisory Board include:

Richard A. Proctor, M.D.
Professor Emeritus, Medical Microbiology and Immunology
Professor Emeritus, Department of Medicine
University of Wisconsin
School of Medicine and Public Health
Madison, Wisconsin

Dr. Henry Chambers, M.D.
San Francisco General Hospital/UCSF
Professor of Medicine
Chief, Division of Infectious Diseases, SFGH

Dr. Joseph Guglielmo, Pharm.D.
University of San Francisco Medical Center
Chair, Department of Clinical Pharmacy
Professor of Clinical Pharmacy
Thomas A. Oliver Chair in Clinical Pharmacy

Dr. Jack Brown, Pharm.D., MS.
Clinical Assistant Professor
School of Pharmacy and Pharmaceutical Services
State University of New York
University at Buffalo

About MicroPhage
Based in Longmont, Colorado, privately held MicroPhage, Inc. develops accelerated, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility/resistance testing. Using its proprietary Bacteriophage Amplification Test (BAT™) platform, the Company has developed patented processes that provide a platform for quick, easy-to-use, inexpensive diagnostic tests. The MicroPhage BATTM test platform does not require any instrumentation and is simple to operate, enabling microbiology testing outside of traditional laboratory settings.